Hints and tips:
Related Special Reports
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...But UBS is attempting to hold on to bankers who specialise in growth areas such as pharmaceuticals, technology, media and telecoms, because the owners of the businesses could be persuaded to become wealth...
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
...It needs further deals to replenish its pharmaceuticals pipeline....
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
Bill Anderson expects further profit declines at the aspirin-to-agriculture conglomerate in 2024
Bill Anderson quashes speculation after suspending break-up of indebted German drugs-to-pesticides group
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
German conglomerate is still struggling with the costly fallout of its $63bn acquisition of Monsanto
...The pharmaceutical industry is close to agreeing a deal with the UK government over drug pricing, according to the chief financial officer of Swiss drugmaker Novartis....
...GLP-1s now underpin a weight loss drug, Wegovy, developed by pharmaceutical group Novo Nordisk....
...That holds true for pharmaceutical companies which are looking a bit peaky. Roche, whose stock has fallen 27 per cent in the past 12 months, is a case in point....
...That is not the case for pharmaceutical companies. Novo Nordisk and Eli Lilly are already striding ahead with anti-obesity treatments....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
Key drugs are due to lose exclusivity in the important US market in 2027
...Many existing drugs derive from natural products, meaning that developing them required less investment in fundamental research than for other kinds of pharmaceuticals....
There is a case for a break-up at the German conglomerate
...German pharmaceutical glassware company Schott Pharma should receive a warm reception when it joins the Frankfurt Stock Exchange later this year....
...But for the German group’s recently installed chief executive Bill Anderson, who has more than two decades of experience in the pharmaceuticals industry, such disappointments are just part of the game....
German group says prospective blockbuster asundexian failed to demonstrate efficacy
German group is examining spinning off its crop sciences or consumer health businesses in effort to restore fortunes
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
...Instead, the UK government set up after Brexit the global Turing scheme providing £110mn in 2023-4 to partly fund 40,000 students....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
International Edition